BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Glycotope Expands GMP Production Facility to 11 kg Antibody per Year


4/5/2011 9:01:59 AM

Berlin, Heidelberg, Germany, April 05, 2011/ b3c newswire / - Glycotope Biotechnology GmbH in Heidelberg, Germany, a full subsidiary of Berlin based Glycotope GmbH, has initiated the setup of further clean room facilities as a first step in the expansion of its GMP-production capacities. By mid 2011, the company will thus be able to produce 4kg of recombinant antibodies per year and up to 11 kg upon completion of works towards the end of 2011. In sum, additional 1400 m² of facility and office space will be created.

The delighted Dr. Steffen Goletz, founder and CEO of Glycotope GmbH comments: “In particular the expansion of our DSP (Downstream Processing) capacities now places us among the top providers of GMP-production for recombinant proteins and in particular antibodies in Germany”.

About Glycotope and GlycotopeBiotechnology

Glycotope-Biotechnology, a full subsidiary of Berlin based Glycotope GmbH was founded upon the acquisition of the GMP-production unit of former Orpegen Pharma GmbH, together with the transfer of manufacturing lines of former Avesta GmbH in Kleinmachnow (Berlin ). With combined more than 140 employees, the Glycotope Group now has grown to one of the largest Biotech organisations in Germany. Glycotope´s product portfolio now encompasses a variety of antibodies and non-antibody biologics, 3 of which are currently undergoing clinical trials. The pipeline includes both new antibodies for tumor therapy (e. g. PankoMab) as well as significantly improved versions of already marketed protein therapeutics (BioBetters). Glycotope´s underlying GlycoExpress™ technology of human cell lines facilitates the optimization of previously disregarded carbohydrate structures found on protein-based drugs (glycosylation). Thus biologics developed in GlycoExpress™ receive a fully human and optimized glycosylation, leading to a largely improved activity, an elongated half-life time and reduced immunogenicity and hence important therapeutic benefits for a significantly increased number of patients.

Contact

Glycotope GmbH

Dr. Franzpeter Bracht, CFO & CBO

Robert-Roessle-Str. 10

13125 BERLIN

Germany

Tel. +49 (0)30 94 89-2600

Fax: +49 (0)30 94 89-2609

franzpeter.bracht@glycotope.com

Glycotope Biotechnology GmbH

Dr. Jens Pohl, COO

Czerny-Ring 22

69115 Heidelberg

Germany

Tel. +49 (0)6221 9105-15

Fax: +49 (0)6221 9105-10

j.pohl@glycotope-bt.com



Read at BioSpace.com

Glycotope
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES